An FDA advisory panel has voted to allow compounding pharmacies to produce seven peptide therapies, though the substances remain illegal to manufacture in the U.S. pending final agency review.

In late July, an FDA advisory panel voted in favor of allowing compounding pharmacies to produce seven peptide therapies, including BPC-157, TB-500, and MOTS-c. Despite the panel's recommendation, these substances remain illegal to manufacture in the U.S. for now. The FDA must now review the data and decide whether to officially authorize their production, a process that could take months or longer.

Regulatory Uncertainty and Next Steps

While the FDA typically follows its advisory committees, the agency has not yet finalized a decision. Experts suggest the FDA could use a formal rulemaking process or potentially place the peptides on a 'Category One list' to expedite availability. Health Secretary Robert F. Kennedy Jr. has publicly supported making these therapies available, though FDA scientists previously raised concerns regarding the lack of rigorous human clinical data for these compounds.

Market Demand and Safety Concerns

Peptides are currently popular in wellness and longevity markets for uses such as injury recovery, muscle growth, and fat loss. Because they are not FDA-approved, many consumers currently obtain them from an unregulated 'gray market' often labeled for research purposes. Proponents argue that bringing these substances into a regulated compounding environment would improve safety, while critics warn that commercial enthusiasm is outpacing clinical evidence.

Access and Implementation

If the FDA authorizes these peptides, they will require a prescription and would be available through compounding pharmacies rather than standard retail pharmacies. Industry representatives note that even with approval, it could take several months for pharmacies to source ingredients and begin production. Currently, there are no widely accepted, evidence-based medical guidelines for the use of these therapies.